Cue Biopharma (NASDAQ:CUE) Price Target Lowered to $4.00 at Stifel Nicolaus

Cue Biopharma (NASDAQ:CUE) had its price target cut by Stifel Nicolaus from $8.00 to $4.00 in a research report report published on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently weighed in on CUE. JMP Securities decreased their price objective on shares of Cue Biopharma from $15.00 to $2.00 and set a market outperform rating for the company in a research report on Friday, July 26th. Piper Sandler decreased their price objective on shares of Cue Biopharma from $8.00 to $3.00 and set an overweight rating for the company in a research report on Friday, July 26th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of Buy and an average target price of $5.00.

Cue Biopharma Trading Down 5.6 %

NASDAQ CUE opened at $0.77 on Tuesday. The company has a market capitalization of $37.43 million, a PE ratio of -0.73 and a beta of 1.96. The company has a fifty day moving average of $0.91 and a 200 day moving average of $1.53. Cue Biopharma has a 1 year low of $0.58 and a 1 year high of $3.25. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.47 and a quick ratio of 2.47.

Cue Biopharma (NASDAQ:CUE) last posted its earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The company had revenue of $2.66 million during the quarter, compared to the consensus estimate of $1.12 million. Cue Biopharma had a negative net margin of 711.84% and a negative return on equity of 128.30%. During the same period in the previous year, the firm posted ($0.29) earnings per share. Research analysts forecast that Cue Biopharma will post -0.93 earnings per share for the current year.

Institutional Trading of Cue Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Legacy Capital Group California Inc. purchased a new stake in shares of Cue Biopharma during the fourth quarter worth about $26,000. Wedmont Private Capital increased its stake in shares of Cue Biopharma by 100.0% during the first quarter. Wedmont Private Capital now owns 40,000 shares of the company’s stock worth $76,000 after purchasing an additional 20,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Cue Biopharma during the 2nd quarter valued at about $66,000. Finally, Vanguard Group Inc. grew its stake in Cue Biopharma by 7.1% during the 1st quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock valued at $4,316,000 after acquiring an additional 150,457 shares in the last quarter. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.